Covant Therapeutics
Covant develops orally active small molecules and novel long-acting subcutaneous injectables targeting critical pathways in human disease. The company focuses on creating first-in-class oral and best-in-class injectable FcRn inhibitors to improve patient options beyond existing biologic therapies. This approach spans small molecules and peptides to advance new therapeutic modalities for various indications.
- Biotechnology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Covant develops orally active small molecules and novel long-acting subcutaneous injectables targeting critical pathways in human disease. The company focuses on creating first-in-class oral and best-in-class injectable FcRn inhibitors to improve patient options beyond existing biologic therapies. This approach spans small molecules and peptides to advance new therapeutic modalities for various indications.